Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/22621
Title: | Late response to anti-TNF-alpha therapy in refractory mucocutaneous lesions of Beh double dagger et's disease |
Authors: | AIKAWA, Nadia Emi; GONCALVES, Carla; SILVA, Clovis Artur Almeida; GONCALVES, Celio; BONFA, Eloisa; CARVALHO, Jozelio Freire de |
Citation: | RHEUMATOLOGY INTERNATIONAL, v.31, n.8, p.1097-1099, 2011 |
Abstract: | Beh double dagger et's disease (BD) is a multisystem chronic inflammatory disorder characterized by oral and genital ulceration and ocular involvement. Recurrent oral and genital ulcers are the most common symptoms of BD and occur in more than 80% of patients. The treatments of these disease manifestations include colchicine, corticosteroids and immunosuppressive drugs in severe cases. Anti-TNF-alpha therapy may be useful in refractory severe BD, particularly for ocular, central nervous system, gastrointestinal and refractory mucocutaneous lesions. During a 2-year period, 280 patients suffering from rheumatic diseases received anti-TNF-alpha agents at the infusion center of our University Hospital. Two patients (0.7%) presented BD; one of them had celiac disease as well, with recalcitrant mucocutaneous lesions that were not responsive to immunosuppressive drugs. We reported those patients who were successfully treated with infliximab and adalimumab, despite their late response. |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - FM/MCM Artigos e Materiais de Revistas Científicas - HC/ICHC Artigos e Materiais de Revistas Científicas - HC/ICr Artigos e Materiais de Revistas Científicas - LIM/17 Artigos e Materiais de Revistas Científicas - LIM/36 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_AIKAWA_Late_response_to_antiTNFalpha_therapy_in_refractory_mucocutaneous_2011.PDF Restricted Access | publishedVersion (English) | 132.56 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.